Heavy menstrual bleeding (HMB), which affects as many as 30% of women, has a well-
established negative impact on quality of life and work productivity [
1
,
2
]. In women with chronic HMB in the absence of known anatomic abnormalities (fibroids,
adenomyosis), options such as non-steroidal anti-inflammatory drugs (NSAIDs) [
[3]
], combined hormonal contraceptives [
[4]
], the levonorgestrel intrauterine system [
[5]
], danazol [
[6]
] and tranexamic acid [
[7]
] show varying degrees of efficacy for reduction of menstrual flow and are often able
to restore normal day-to-day function.To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to ContraceptionAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Daily menstrual blood loss and quality of life in women with heavy menstrual bleeding.Womens Health. 2012; 8: 503-511
- Abnormal uterine bleeding in premenopausal woman. SOGC Clinical Practice Guideline 292.J Obstet Gynecol Can. 2013; 35: S1-S28
- Nonsteroidal anti-inflammatory drugs for heavy menstrual bleeding.Cochrane Database Syst Rev. 2013; 000400
- Effective treatment of heavy menstrual bleeding with estradiol valerate and dienogest: a randomized controlled trial.Obstet Gynecol. 2011; 117: 777-787
- Modern management of abnormal uterine bleeding—the levonorgestrel intra-uterine system.Best Pract Res Clin Obstet Gynaecol. 2007; 21: 1107-1121
- Reduction of menstrual blood loss by danazol in unexplained menorrhagia: lack of effect of placebo.Br J Obstet Gynaecol. 1980; 87: 1152-1158
- Tranexamic acid treatment for heavy menstrua lbleeding: a randomized controlled trial.Obstet Gynecol. 2010; 116: 865-875
- Use of intravenous Premarin in the treatment of dysfunctional uterine bleeding—a double-blind randomized controlled study.Obstet Gynecol. 1982; 59: 285-291
- A new progestogen-only medical therapy for outpatient management of acute, abnormal uterine bleeding: a pilot study.Am J Obstet Gynecol. 2013; 208: 499.e1-499.e5
- Oral medroxyprogesterone acetate and combination oral contraceptives for acute uterine bleeding. A Randomized Controlled Trial.Obstet Gynecol. 2006; 108: 924-929
- Cyclic changes in endometrial tissue plasminogen activator and plasminogen activator inhibitor type 1 in women with normal menstruation and essential menorrhagia.Am J Obstet Gynecol. 1994; 171: 178-183
- A benefit-risk review of systemic haemostatic agents. Part 1: in major surgery.Drug Saf. 2008; 31: 217-230
- Treatment with tranexamic acid during pregnancy and the risk of thrombo-embolic events.Thromb Haemost. 1993; 70: 238-240
- A systematic review and meta-analysis of the effect of prophylactic tranexamic acid treatment in major benign uterine surgery.Int J Gynaecol Obstet. 2017; 136: 120-127
- Tranexamic acid update in trauma.Crit Care Clin. 2017; 33: 85-99https://doi.org/10.1016/j.ccc.2016.08.004
- Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial.Lancet. 2017; 389: 2105-2116
- Tranexamic acid to be available OTC for menstrual bleeding.(GPonline. April 6, 2010. at)https://www.gponline.com/tranexamic-acid-made-available-otc-menstrual-bleeding/obstetrics/article/994087Date accessed: November 18, 2017
- Cyclo-F 500mg film-coated tablets: Tranexamic acid.in: UK public assessment report [online]. 2010 ([Available:http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con082059.pdf [Accessed Nov 20, 2017]])
- Lysteda (Tranexamic acid) US FDA Prescribing information, side effects and uses.(Accessed at)https://www.drugs.com/pro/lysteda.htmlDate: 2017
- Canadian Cyklokapron product monograph.(at)https://www.pfizermedicalinformation.ca/en-ca/product-monograph#cDate accessed: November 25, 2017
- Case report: Tranexamic acid and intracranial thrombosis.Lancet. 1976; 2: 49
- Case report: Tranexamic acid, intrauterine contraceptive devices and fatal cerebral thrombosis.Brit J Obstet Gynaecol. 1982; 89: 681-682
- Central venous stasis retinopathy following the use of tranexamic acid.Retina. 1990; 10: 181-184
- Tranexamic acid-induced visual impairment in a hemodialysis patient.Clin Exp Nephrol. 2003; 7: 311-314
- Retinal artery occlusion associated with tranexamic acid therapy.Am J Ophthalmol. 1988; 105: 688-689
- Combined treatment with tranexamic acid and oral contraceptive pill causes coronary ulcerated plaque and acute myocardial infarction.Cardiovasc Drugs Ther. 2004; 18: 239-240
- No increased risk of venous thrombosis in women taking tranexamic acid.Thromb Haemost. 2001; 86: 714-715
- Tranexamic acid therapy: effective in treatment in heavy menstrual bleeding: Clinical update on safety.Ther Adv. 1991; 4: 1-8
- Safety of tranexamic acid in women with heavy menstrual bleeding: an open-label extension study.Womens Health. 2011; 7: 591-598
- Increased risks of circulatory diseases in late pregnancy and puerperium.Epidemiology. 2001; 12: 456-460
- Pregnancy, the postpartum period and prothrombotic defects: risk of venous thrombosis in the MEGA study.J Thromb Haemost. 2008; 6: 632-637
- Benefit-risk review of systemic haemostatic agents part 2: in excessive or heavy menstrual bleeding.Drug Saf. 2008; 31: 275-282
- Treatment with the fibrinolytic inhibitor tranexamic acid: risk for thrombosis.Acta Obstet Gynecol Scand. 1990; 69: 353-354
- Range of published estimates of venous thromboembolism incidence in young women.Contraception. 2007; 75: 328-336
- Oral contraceptives and venous thromboembolism consensus opinion from an international workshop held in Berlin, Germany in December 2009.J Fam Plann Reprod Health Care. 2010; 36: 117-122
- Oral hormonal contraception and venous thromboembolism.Contraception. 2014; 89: 235-236
- Drospirenone-containing oral contraceptive pills and the risk of venous thromboembolism: a systematic review of observational studies.BJOG. 2017; 124: 1490-1499https://doi.org/10.1111/1471-0528.14623
Article info
Publication history
Published online: February 22, 2018
Accepted:
February 15,
2018
Received in revised form:
February 14,
2018
Received:
December 6,
2017
Footnotes
☆Funding: The authors have had no involvement with the company marketing TXA (including speaker’s bureaus or advisory boards) and this commentary was developed without funding from agencies in the public, commercial, or not-for-profit sectors.
Identification
Copyright
© 2018 Elsevier Inc. All rights reserved.
